05B4 Chapman, Andrew - Thomas Jefferson University - Thomas Jefferson University
Dr. Chapman

Andrew Chapman, DO, FACP

Contact Dr. Chapman

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 923-5676

Most Recent Peer-reviewed Publications

  1. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer
  2. Silver oncologic tsunami: Quality issues in the senior adult oncology population
  3. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer
  4. Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors
  5. Randomized phase II trial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer: An eastern cooperative oncology group study
  6. Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience
  7. Senior adult oncology: Three cases of advanced cancer in patients of advanced age
  8. Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts
  9. Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy
  10. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy
  11. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance
  12. Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer
  13. Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma
  14. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine